Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selgantolimod in Viremic Chronic Hepatitis B
NCT03615066Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of selgantolimod in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Aug 2018; status: completed.
02
Drugs
selgantolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03615066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615066.